BioNotebook: Seven deals and updates, including 190 pre-merger layoffs at Auxilium
This article was originally published in Scrip
Auxilium cutting 190 jobs ahead of QLT merger; Cempra gets $10m milestone payment; Ligand, CURx sign license deal; Telik will soon be MabVax after merger; Ophthotech earns $50m fee from Novartis; Momenta exercises option with AnaptysBio; and J&J initiates neuroscience collaboration.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.